Kestinlyo

Ebastine, the active ingredient in Kestinlyo, is a H1 antihistamine presented as an oral tablet for oral use. It works by selectively blocking peripheral H1 receptors, thereby preventing histamine‑mediated allergic responses. The medication is indicated for the relief of nasal congestion, sneezing, itching and watery eyes associated with allergic rhinitis, as well as for reducing hives and itching in chronic urticaria. It is intended for use in adult and adolescent patients under medical supervision.

GNH USA supplies Kestinlyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ebastine, marketed as Kestinlyo, is an H1 antihistamine that addresses allergic conditions by inhibiting histamine activity.

Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge. Seasonal allergic rhinitis: provides symptom relief during pollen seasons. Chronic urticaria: diminishes the number and severity of hives and associated itching. Allergic conjunctivitis: alleviates eye itching and redness caused by histamine release.

Like all antihistamines, ebastine may cause unwanted effects, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Dry mouth: sensation of oral dryness. - Drowsiness: transient sleepiness. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Anaphylaxis: acute allergic reaction with airway compromise. - Elevated liver enzymes: signs of hepatic stress.

When prescribing ebastine, clinicians should consider several precautionary measures to ensure safe use. - Hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Renal impairment: use with caution in severe renal disease. - Known hypersensitivity: avoid in individuals with documented allergy to ebastine or excipients. - Concomitant CNS depressants: monitor for enhanced drowsiness when combined with sedatives. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Ebastine can interact with other medicines, altering its plasma levels or enhancing side effects.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition markedly increases ebastine exposure. - Erythromycin: macrolide antibiotic that raises ebastine concentrations. - Itraconazole: azole antifungal leading to significant plasma level elevation. - Cimetidine: H2‑blocker that can increase ebastine levels. - Grapefruit juice: may enhance systemic exposure through CYP3A4 inhibition.

Moderate Interactions (Monitor Closely): - Alcohol: may potentiate drowsiness and central nervous system effects. - Other antihistamines: concurrent use can increase sedation risk.